Parkinson's disease therapeutic - BenevolentAI
Latest Information Update: 03 Nov 2023
At a glance
- Originator BenevolentAI
- Class Antiparkinsonians
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Parkinson's disease